Optimal standard regimen and predicting response to docetaxel therapy

Identifying and Predicting the Effectiveness of Carboplatin In Vivo and In Vitro and Evaluating its Combination with Paclitaxel

“…2 and expressed in Eq. 4 has been constructed as described in earlier studies of other chemotherapeutics [17][18][19][20][21][22]. The conformity between the predicted therapeutic response of cancer to carboplatin and the actual one in vivo and in vitro strengthens the confidence in both assays so that results of either assay can be predicted from results of the other one as shown in section of results and analysis.…”

“…The tumor growth/ shrinkage constant at a certain time expresses the rate of the difference between Mitosis and Apoptosis with respect to the total number of the tumor cells (M-A) that characterize the tumor response at that time [28]. If rate of mitosis is greater than that of apoptosis, tumor grows by growth constant of ln 2 t D , and vice versa if rate of mitosis is less than that of apoptosis, tumor shrinks by shrinkage constant of ln 2 t 1=2 [17][18][19][20][21][22].…”

“…The clinical staging model presented by Moawad showed that the tumor histologic grade (H G ) that expresses doubling time-energy conversion in tumor cells can be identified using Emad formula [10][11][12][13][14][15][16][17][18][19][20][21][22][29][30][31][32][33] according to the tumor response as follows:…”

“…Thus to apply Eq. 1 in the shrinkage case, the apoptotic tumor portion of half-life time (t 1/2 ) would be replaced by the growth portion of doubling time (t D ) which had been prevented first from mitosis whose rate of growth is inversely proportional to the rate of the shrinkage of the apoptotic portion as follows [17]:…”

“…Recently, targeting patientpersonalized cancer medicine, Moawad presented in vivo and in vitro models for identifying effectiveness of cancer therapy at the cellular level. In those models, difference induced in patient-specific histologic grade (H G ) before and after therapy expresses the antitumor activity of the cancer medicine [17][18][19][20][21][22]. Thus predicting patients' response to therapy by identifying patient-specific H G would enable to avoid chemo-resistance to carboplatin observed in some malignancies by more accurate dose estimates for this drug whose full therapeutic potential is yet to be realized [17].…”